No Data
No Data
United Laboratories International Holdings' (HKG:3933) Three-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Brokerage morning meeting highlights: Now is the right time for AI healthcare layout.
In today's Brokerage morning meeting, Sinolink proposed that the layout of AI in healthcare is timely; HTSC expressed a bullish outlook on the product upgrades and commercial breakthroughs of AI applications in China by 2025; China Securities Co.,Ltd. believes that the turning point in the IDC Industry is approaching, and a new cycle is expected to begin.
UOB Kay Hian Downgrades The United Laboratories International Holdings to Hold From Buy; Price Target Is HK$13
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
The Market Doesn't Like What It Sees From The United Laboratories International Holdings Limited's (HKG:3933) Earnings Yet
UNITED LAB (03933.HK): The UBT251 injection for chronic kidney disease has received implied clinical trial approval.
On January 22, Gelonghui reported that UNITED LAB (03933.HK) announced that on January 20, 2025, its wholly-owned subsidiary UNITED BIOTECH (Zhuhai Hengqin) Co., Ltd. obtained the clinical trial implied permission from the National Medical Products Administration of China for the phase II clinical trial registration application of the Innovative Drug UBT251 injection for the indication of chronic kidney disease, with acceptance number CXHL2401227. UBT251 is a long-acting GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic peptide)/GCG (glucagon) triple-target compound.